Therefore, our research aimed to develop a deeper exploration of genomic alterations in HER2‐positive patients undergoing NAT and determine whether genetic mutations can be used as biomarkers to predict the efficacy of neoadjuvant therapy, exploring the relationship between genetic mutations and patient prognosis to the greatest extent among HER2‐positive BC patients. The gene discussed is ERBB2; the disease is breast cancer.